The combination of RIB with IFN β-1b and Lopinavir–Ritonavir therapy is currently in clinical trials for treating SARS-CoV-2 infection (77), which has been shown to significantly alleviate the COVID-19 symptoms and suppress IL-6 levels in serum. Here, IL6 is linked to COVID-19.